New drugs for the treatment of Parkinson's disease

Pharmacotherapy

Volumn 20, Issue 1 II, 2000, Pages

  LeWitt, Peter A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Neuroscience Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

ARTICLE; DROWSINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HUMAN; NAUSEA; PARKINSON DISEASE; SWEATING; VERTIGO; VOMITING;

EID: 0033967073     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.2.26s.34631     Document Type: Article

References (47)

1. LeWitt PA. The pharmacology of levodopa in treatment of Parkinson's disease: an update. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Handbook of experimental pharmacology, vol 88. Berlin: Springer-Verlag, 1989;325-84.
2. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-9.
3. LeWitt PA. Therapy with dopaminergic drugs in Parkinson disease. In: Koller WC, ed. Handbook of Parkinson's disease, 2nd ed. New York: Marcel Dekker, 1992;469-507.
4. LeWitt PA, Calne DB. Experiences with dopamine agonists in Parkinson s disease and related disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W, eds. Lisuride and other dopamine agonists. New York: Raven Press, 1983;473-80.
5. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A). a novel D agonist. Pharm Biochem Behav 1991;38:147-54.
6. Bowen WP, Coldwell MC, Hicks FR, et al. Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D receptors. Br J Pharmacol 1993;110:93.
7. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-41.
8. Thalamas C, Rayet S, Brefel C, et al. Effect of food on the pharmacokinetics of ropinirole in patients with Parkinson's disease. Mov Disord 1996;11(suppl 1):138.
9. Brooks DJ, Turjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinsons disease. J Neural Transm Suppl 1995;45:231-8.
10. Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm Suppl 1995;45:213-24.
11. 2-like receptor agonist. Eur J Pharmacol 1994;265:17-26.
12. Vidailhet MJ, Bonet AM, Belal S, et al. Ropinirole without levodopa in Parkinson's disease [letter]. Lancet 1990;36:316-17.
13. Wheadon D, Wilson-Lynch K, Gardiner D, Kreider M. The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicenter double-blind study [abstr]. Neurology 1996;46:A159.
14. Wheadon DE, Wilson-Lynch K, Gardiner D, Kreider MS. Ropinirole, a non-ergoline D agonist, is effective in early parkinsonian patients not treated with levodopa [abstr]. Mov Disord 1996;11(suppl 1):162.
15. Rascol O. A double blind L-dopa controlled study of ropinirole in de novo patients with Parkinson's disease [abstr]. Mov Disord 1996;11(suppl 1):139.
16. Rascol O. A double-blind L-dopa-controlled study of ropinirole in patients with early Parkinson's disease [abstr]. Neurology 1996;46:A160.
17. Ropinirole 053 Study Group. A double-blind comparison of ropinirole vs bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-dopa [abstr]. Mov Disord 1996;11(suppl 1):188.
18. Ropinirole 053 Study Group. To compare the efficacy at six months of ropinirole versus bromocriptine as early therapy in parkinsonian patients [abstr]. Mov Disord 1996;11(suppl 1):188.
19. Korczyn AD. A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease [abstr]. Neurology 1996;46:A159.
20. Kreider M, Knox S, Gardiner D, Wheadon D. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstr]. Neurology 1996;46:A475.
21. Kreider MS, Knox S, Gardiner D, Wheadon DE. The efficacy of ropinirole, a non-ergoline D agonist, as an adjunct to L-dopa (DCl) in patients with Parkinson's disease [abstr]. Mov Disord 1996;11(suppl 1):156.
22. Aitken C, Fuell D, Laroche J. A double-blind study comparing ropinirole and bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-dopa. Presented at the 28th Annual Meeting of the American Society of Consultant Pharmacists, Nashville, TN, November 13-16, 1996.
23. Camacho-Ochoa M, Walker EL, Evans DL, Piercey MF. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. Neurosci Lett 1995;196:97-100.
24. 2 receptor agonist. Eur J Pharmacol 1992;215:161-70.
25. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
26. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl 1995;45:225-30.
27. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled parallel-group study. Neurology 1997;49:162-8.
28. Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons [abstr]. Mov Disord 1996;1 (suppl 1):191.
29. Grondin R, Blanchet PJ, Goulet M, et al. Cabergoline as single therapy has a sustained antiparkinsonian actions with less dyskinesia in MPTP monkeys [abstr]. Mov Disord 1996;11(suppl 1):64.
30. Arai N, Isaji M, Miyata H, et al. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J Neural Transm 1995;10:55-62.
31. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587-90.
32. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Adv Neurol 1990;53:539-43.
33. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-4.
34. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-5.
35. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-41.
36. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-8.
37. Del Dotto P, Colzi A, Pardini C, et al. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. J Neural Transm Suppl 1995;45:259-65.
38. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-5.
39. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454-6.
40. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
41. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
42. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-51.
43. Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-65.
44. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995;18:333-7.
45. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/ carbidopa action in Parkinsonian patients. Neurology 1993;43:2685-8.
46. Dorflinger EE, Rajput A, Martin W, et al. Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson disease patients who exhibit end-of-dose wearing-off. Neurology 1996;46:A474-5.
47. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The tolcapone stable study group. Neurology 1997;49:665-71.